At the recent British Healthcare Trades Association (BHTA) Conference 2024, Barney Willis, Deputy Head of Life Sciences at the Department for Business and Trade (DBT), explained how DBT provides practical support to UK medtech SMEs with exporting.

The BHTA Conference 2024 focused on the UK healthtech landscape over the next five years. It was a chance for BHTA members to hear from senior government and NHS speakers about how the changes made today will impact the future of the health service.

Barney began by explaining what the DBT does. The department brings together business and trade in a single department. Export and investment are the two pillars of the department. DBT also opens up new markets for businesses by removing barriers and negotiating trade deals, which can lead to practical opportunities opening up.

Barney provided some insightful UK medtech sector statistics. See them in the slide below.

Despite the UK having an innovative, productive, and fast-growing medtech sector, UK medtech exports are low relative to international comparators, he said. The UK imports more than it exports.

The key point from Barney’s presentation is that the DBT provides practical advice and support to SMEs to help them grow and export, which involves non-stop engagement. Barney outlined some of the practical support available to SMEs in the slide below.

Barney said: “We will competitively recruit between 10 and 14 companies, which will be UK SMEs that have got something competitive that we think has a chance of being successful in an overseas market.

“For example, I’m flying to Saudi Arabia with about 10 companies, which we recruited from across the assistive tech and medtech sectors, and we will use the convening power of the British Embassy to get them into rooms they wouldn’t otherwise get into.”

Importantly for SMEs, DBT has a network of international trade advisers across the south, midlands, and north of England, Barney explained. These advisers provide businesses with free and impartial export support. Additionally, they can help firms develop their export strategy, access masterclasses, link firms to specialist export advisers, and help firms make the most of DBT’s global network so they can grow their business overseas.

DBT’s overseas network spans over 100 markets with a global reach in more than 170 countries. These include Canada, the US, Germany, UAE, Japan, Spain, New Zealand, China, and more.

Barney added: “DBT has embedded staff in most of the markets you’re likely to care about, and certainly the large ones. These will be, in many cases, specialists who know the sector in their country. They will often be locally engaged.”

The British Healthcare Trades Association (BHTA) recently hosted another successful conference that brought together healthcare leaders and suppliers to discuss how the changes made today will impact the future of the health service.

The sellout BHTA Conference 2024, ‘Health Tech in the UK: The next 5 years’, took place at the Northampton Town Centre Hotel on 21 May and was sponsored by Verlingue.

Boasting an impressive roster of key government and NHS speakers, engaging presentations throughout the day included topics on the MedTech Strategy one year on, the Procurement Act 2023, late-stage medical device assessments, practical export support for UK SMEs, UK medical device regulation changes, and much more.

Attendees had the chance to ask the speakers important questions during two Q&A panel discussions throughout the day.

The conference kicked off with a welcome from BHTA CEO David Stockdale, who highlighted some of the BHTA’s successful campaigns, how the BHTA lobbies to government to ensure its members’ voices are heard, and an overview of the BHTA Conference 2024.

Next, Lord Markham, Parliamentary Under-Secretary from the Department of Health and Social Care (DHSC), shared his opening remarks. Lord Markham outlined that the UK has massive potential to transform the medtech landscape over the next five years and highlighted relevant and successful government initiatives like Innovative Devices Access Pathway (IDAP), the MedTech Strategy, and late-stage medtech assessments.

David Lawson, Director of MedTech for DHSC, delivered a presentation titled ‘Value Not Cost’. He discussed the ‘The medical technology strategy: one year on’ report, the issues DHSC is trying to solve when it comes to the medtech sector, and value-based procurement.  

Fiona Hilton, Director of Commercial Best Practice & Engagement for NHS England, discussed the Strategic Framework for NHS Commercial. Her presentation delved into how the Procurement Act 2023 will significantly change how the NHS works with suppliers and the Strategic Framework for NHS Commercial.

Andrew New, CEO of NHS Supply Chain, presented ‘One Year On – More to Come’. He talked about how NHS Supply Chain will change over the next five years to make it better to work with, and how it aims to enable an optimised, resilient, and sustainable supply chain.

Mark Chapman, Interim Director Medical Technology Digital & Diagnostics at NICE, commenced the afternoon presentations. His presentation was titled ‘NICE HealthTech Assessment: Focus on What Matters Most’. Mark explained the NICE HealthTech Assessment lifecycle approach and late-stage medical device assessments.  

Barney Willis, Deputy Head of Life Sciences for the Department for Business and Trade (DBT), explained how DBT provides practical support to UK medtech SMEs with exporting. Barney provided an insight into how DBT promotes innovative UK medtech companies in key global export markets.

Before the closing remarks, Laura Squire, Chief Healthcare Quality & Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA), delivered the final BHTA Conference 2024 presentation. Her talk, ‘How Regulation of Medical Devices in the UK is Changing’ explored where UK medical device regulation is at now and what the future looks like, alongside international recognition of medical devices.

Positive feedback from the day included:

“An excellent set of speakers and some thought-provoking questions. Given the make-up of BHTA membership, it was good to see several references to the importance of SME business from the speakers.”

“A very good event with really good Q&A sessions. The speakers and the topics they covered should have been of real value to members. I always go looking for 3 or 4 golden nuggets at a day like this, and there were several.”

“It was a really informative day, great speakers, content, location, room, and lunch.”

“It was obvious from how well it went that a lot of work has gone into it, so I hope all the team involved are justifiably proud of the day.”